Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4375MR)

This product GTTS-WQ4375MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4375MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ45MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ4197MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ7395MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ15009MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ11742MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ10620MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ11517MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ1602MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW